Pfizer/Pharmacia Clears FTC: Viagra Patent Strategy, HRT Safety Are Factors
Executive Summary
Pfizer's patent defense strategy for Viagra is one reason the Federal Trade Commission is requiring the divestiture of Phase II erectile dysfunction disorder agents as a condition of the Pfizer/Pharmacia merger
You may also be interested in...
HRT Class Labeling Should Not Cover Topical Estrogens, Pharmacia Says
Topical hormone therapy drugs should be exempt from FDA's proposed estrogen class labeling incorporating safety information from the Women's Health Initiative study, Pharmacia maintained in comments submitted to the agency
Pfizer R&D Reshuffling Deals Out Pharmacia’s Investment In Sugen
Pfizer will cease investment in the biotech company Sugen as part of a reorganization of Pfizer/Pharmacia's combined R&D facilities
HRT Class Labeling Should Not Cover Topical Estrogens, Pharmacia Says
Topical hormone therapy drugs should be exempt from FDA's proposed estrogen class labeling incorporating safety information from the Women's Health Initiative study, Pharmacia maintained in comments submitted to the agency